source
- Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale productionAfter mastering large‑scale mRNA manufacturing during the COVID‑19 pandemic, the sector is now turning its attention to delivering individualized vaccines to patients quickly. The recent clinical…
- Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next yearInhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers. The data suggest the agent may also enhance responses when paire…